Apremilast

Creative Commons License

Kundakci N.

TURKDERM-TURKISH ARCHIVES OF DERMATOLOGY AND VENEROLOGY, cilt.56, ss.70-74, 2022 (ESCI) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 56
  • Basım Tarihi: 2022
  • Doi Numarası: 10.4274/turkderm.galenos.2022.90359
  • Dergi Adı: TURKDERM-TURKISH ARCHIVES OF DERMATOLOGY AND VENEROLOGY
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.70-74
  • Anahtar Kelimeler: Psoriasis, phosphodiesterase inhibitor, apremilast, ORAL PHOSPHODIESTERASE-4 INHIBITOR, SEVERE PLAQUE PSORIASIS, TRIALS ESTEEM 1, PHASE-III, PDE4 INHIBITOR, SAFETY, EFFICACY, MODERATE, THERAPIES, ARTHRITIS
  • Ankara Üniversitesi Adresli: Evet

Özet

Apremilast is an orally used small-molecule inhibitor of phosphodiesterase-4. It has been approved for the treatment of adult patients with psoriatic arthritis and moderate to severe plaque psoriasis. Clinical studies have reported that it is also effective in hairy skin and nail psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis. In psoriasis vulgaris, a PASI75 response was achieved in 30-70% of the patients in 12-16 weeks. It is generally well-tolerated, and its most common side effects are diarrhea, headache, and nausea, all of which disappear in time.